Equities

Hinova Pharmaceuticals Inc

688302:SHH

Hinova Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)25.37
  • Today's Change-12.33 / -32.71%
  • Shares traded711.33k
  • 1 Year change-44.28%
  • Beta--
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,1041,568901
Total Receivables, Net13199.97
Total Inventory0.010.010.00
Prepaid expenses302531
Other current assets, total0.040.0413
Total current assets1,1471,611955
Property, plant & equipment, net2038727
Goodwill, net------
Intangibles, net3132--
Long term investments1105.00--
Note receivable - long term------
Other long term assets------
Total assets1,4921,735982
LIABILITIES
Accounts payable939083
Accrued expenses5.009.178.73
Notes payable/short-term debt0300
Current portion long-term debt/capital leases3.772.452.80
Other current liabilities, total5.206.7097
Total current liabilities107138191
Total long term debt9.083.311.11
Total debt13363.91
Deferred income tax------
Minority interest------
Other liabilities, total8.558.101.15
Total liabilities124150194
SHAREHOLDERS EQUITY
Common stock999974
Additional paid-in capital2,5582,4821,409
Retained earnings (accumulated deficit)(1290)(996)(695)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.110.14(0.07)
Total equity1,3671,585789
Total liabilities & shareholders' equity1,4921,735982
Total common shares outstanding999999
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.